Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital

References

1. 1.↵
   World Health Organization. Global hepatitis report 2017. [Updated 2017; 2022 June 1]. Available from: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en
2. 2.↵
   1. Aljumah AA,
   2. Abaalkhail F,
   3. Al-Ashgar H,
   4. Assiri A,
   5. Babatin M,
   6. Al Faleh F, et al.

   Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift. Saudi J Gastroenterol 2016; 22: 269-281.

   OpenUrl
3. 3.↵
   The European Association for the Study of the Liver. Special report: hepatitis C elimination plan consensus recommendations for the Kingdom of Saudi Arabia. [Updated 2018; 2022 July 6]. Available from: https://easl-ilf.org/wp-content/uploads/2018/12/saudi.pdf
4. 4.↵
   1. Manns MP,
   2. Wedemeyer H,
   3. Cornberg M.

   Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-1359.

   OpenUrlFREE Full Text
5. 5.↵
   1. Cacoub P,
   2. Gragnani L,
   3. Comarmond C,
   4. Zignego AL.

   Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014; 46: S165-S173.

   OpenUrl
6. 6.↵
   1. Levin A,
   2. Stevens PE,
   3. Bilous RW,
   4. Coresh J,
   5. De Francisco ALM,
   6. De Jong PE, et al.

   Kidney disease: improving global outcomes (KDIGO). CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Sup 2013; 3: 1-150.

   OpenUrl
7. 7.↵
   1. Ladino M,
   2. Pedraza F,
   3. Roth D.

   Hepatitis C virus infection in chronic kidney disease. J Am Soc Nephrol 2016; 27: 2238-2246.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Pawlotsky JM,
   2. Negro F,
   3. Aghemo A,
   4. Berenguer M,
   5. Dalgard O,
   6. Dusheiko G, et al.

   EASL recommendations on treatment of hepatitis C: final update of the series*. J Hepatol 2020; 73: 1170-1218.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Shah N,
   2. Pierce T,
   3. Kowdley KV.

   Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2013; 22: 1107-1121.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Ghany MG,
    2. Morgan TR.

    Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 2020; 71: 686-721.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Pearlman BL,
    2. Hinds AE.

    Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir. Aliment Pharmacol Ther 2018; 48: 914-923.

    OpenUrl
12. 12.↵
    1. Lamb YN.

    Glecaprevir/pibrentasvir: first global approval. Drugs 2017; 77: 1797-1804.

    OpenUrl
13. 13.↵
    AbbVie. AbbVie’s MAVIRET approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes. [Updated 2017; 2022 July 19]. Available from: http://www.abbvie.com/
14. 14.↵
    AbbVie. Mavyret (glecaprevir/pibrentasvir) US prescribing information. [Updated 2019; 2022 July 23]. Available from: https://www.rxabbvie.com/pdf/mavyret_pi.pdf
15. 15.↵
    1. Kwo PY,
    2. Poordad F,
    3. Asatryan A,
    4. Wang S,
    5. Wyles DL,
    6. Hassanein T, et al.

    Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol 2017; 67: 263-271.

    OpenUrlCrossRef
16. 16.↵
    1. Asselah T,
    2. Kowdley KV,
    3. Zadeikis N,
    4. Wang S,
    5. Hassanein T,
    6. Horsmans Y, et al.

    Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 2018; 16: 417-426.

    OpenUrl
17. 17.↵
    1. Brown RS Jr.,
    2. Buti M,
    3. Rodrigues L,
    4. Chulanov V,
    5. Chuang WL,
    6. Aguilar H, et al.

    Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol 2020; 72: 441-449.

    OpenUrl
18. 18.↵
    1. Atsukawa M,
    2. Tsubota A,
    3. Toyoda H,
    4. Takaguchi K,
    5. Nakamuta M,
    6. Watanabe T, et al.

    The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther 2019; 49: 1230-1241.

    OpenUrl
19. 19.↵
    1. Gane E,
    2. Lawitz E,
    3. Pugatch D,
    4. Papatheodoridis G,
    5. Bräu N,
    6. Brown A, et al.

    Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 2017; 377: 1448-1455.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Chayama K,
    2. Suzuki F,
    3. Karino Y,
    4. Kawakami Y,
    5. Sato K,
    6. Atarashi T, et al.

    Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol 2018; 53: 557-565.

    OpenUrl
21. 21.↵
    1. Shobokshi OA,
    2. Serebour FE,
    3. Skakni L,
    4. Al-Saffy YH,
    5. Ahdal MN.

    Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999; 58: 44-48.

    OpenUrlCrossRefPubMedWeb of Science